Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 31–40 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 31
- Medicine slug
- adalimumab-bwwd
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
64%
- Numeric value
- 64
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef25af7e-6267-409a-8d68-de51eb48812a (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c361dd60-c88d-4f3c-b98c-79687bbc3450 (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7345f276-102e-4175-b7ef-ff1706b05472 (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c24655e5-796e-4127-b716-92f08d649c83 (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
Projected row 32
- Medicine slug
- adalimumab-bwwd
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
10 to 20 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef25af7e-6267-409a-8d68-de51eb48812a (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c361dd60-c88d-4f3c-b98c-79687bbc3450 (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7345f276-102e-4175-b7ef-ff1706b05472 (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c24655e5-796e-4127-b716-92f08d649c83 (opens source in a new tab)
Adalimumab-Bwwd label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
Projected row 33
- Medicine slug
- adalimumab-ryvk
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
64%
- Numeric value
- 64
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba9dd71c-13c9-4cfe-84a2-b4f17d1c583f (opens source in a new tab)
Adalimumab-Ryvk label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12f609c9-2088-bb05-e063-6394a90a9ecc (opens source in a new tab)
Adalimumab-Ryvk label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce1590f-9e47-4c4d-9437-cfb18b779a75 (opens source in a new tab)
Adalimumab-Ryvk label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
Projected row 34
- Medicine slug
- adalimumab-ryvk
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
10 to 20 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba9dd71c-13c9-4cfe-84a2-b4f17d1c583f (opens source in a new tab)
Adalimumab-Ryvk label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12f609c9-2088-bb05-e063-6394a90a9ecc (opens source in a new tab)
Adalimumab-Ryvk label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce1590f-9e47-4c4d-9437-cfb18b779a75 (opens source in a new tab)
Adalimumab-Ryvk label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
Projected row 35
- Medicine slug
- adapalene
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 49
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
7 to 51 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3b6f3c3-d615-4b00-a76f-134b75e30a50 (opens source in a new tab)
Adapalene label
Version not recorded · Effective date not recorded
The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a0d9a0d-a9f3-4eb9-be76-166ef182d13a (opens source in a new tab)
Adapalene label
Version not recorded · Effective date not recorded
The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0031324-92a6-4c11-90e2-c2818f7278ec (opens source in a new tab)
Adapalene label
Version not recorded · Effective date not recorded
The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aacd5ec4-e2fa-460e-aaae-a0aba5c052e5 (opens source in a new tab)
Adapalene label
Version not recorded · Effective date not recorded
The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dd6d825-f7c4-4a86-82cc-fcbb41df8542 (opens source in a new tab)
Adapalene label
Version not recorded · Effective date not recorded
The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca37576a-09aa-4ee8-9dc4-8ad76b999fcf (opens source in a new tab)
Adapalene label
Version not recorded · Effective date not recorded
The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
Projected row 36
- Medicine slug
- adefovir-dipivoxil
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
59%
- Numeric value
- 59
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08e07fae-3191-b6a3-c894-d3a8cc53923f (opens source in a new tab)
Adefovir Dipivoxil label
Version not recorded · Effective date not recorded
Based on a cross study comparison, the approximate oral bioavailability of adefovir from adefovir dipivoxil is 59%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e047f3b2-feae-4c5e-9d07-1fefb4c0ec25 (opens source in a new tab)
Adefovir Dipivoxil label
Version not recorded · Effective date not recorded
Based on a cross study comparison, the approximate oral bioavailability of adefovir from Adefovir Dipivoxil Tablets is 59%.
Projected row 37
- Medicine slug
- adefovir-dipivoxil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
7.48 ± 1.65 hours
- Numeric value
- 7.48
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08e07fae-3191-b6a3-c894-d3a8cc53923f (opens source in a new tab)
Adefovir Dipivoxil label
Version not recorded · Effective date not recorded
Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 ± 1.65 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e047f3b2-feae-4c5e-9d07-1fefb4c0ec25 (opens source in a new tab)
Adefovir Dipivoxil label
Version not recorded · Effective date not recorded
Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 ± 1.65 hours.
Projected row 38
- Medicine slug
- albendazole
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
8 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:594f7aab-b336-4d6d-b702-a33346c69645 (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1977a867-0ee1-44c0-8da3-fe59c48699f5 (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06b5eefc-0b95-4862-b9b6-770063f2adf0 (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d6856a3-583e-41d4-b73d-6867cbb9778c (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b4945c7-56e9-47ed-a7ac-5078a1a50b85 (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ac95554-94c9-1f38-8f49-ec11979e4ba4 (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c7b8cb-a81f-4b13-b3c4-f6edaf880d3b (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74aeb307-b408-47b1-bd8f-fe7eeb844466 (opens source in a new tab)
Albendazole label
Version not recorded · Effective date not recorded
The mean apparent terminal elimination half-life of albendazole sulfoxide ranged from 8 hours to 12 hours in 25 healthy subjects, as well as in 14 hydatid and 8 neurocysticercosis patients.
Projected row 39
- Medicine slug
- albuterol
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 113
- Source count
- 38
- Agreement rate
- 0.421053
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9b287b-e4a4-4c12-ad2f-6b7d55b20dc6 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40f3cdbc-c9ee-4a3c-8061-a44b9a1d035c (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd47559a-84f6-42a5-a00e-48754505418e (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9324e2eb-26fd-4f14-9f10-e5aa467306f4 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
The corresponding effective half-life was approximately 5 hours, which was consistent with the elimination half-life following both single- or multiple-dose administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a22af54a-c010-ab8b-e053-2a95a90a8862 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:667ce3ec-5217-4b10-b712-f3e54fbbf087 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
The corresponding effective half-life was approximately 5 hours, which was consistent with the elimination half-life following both single- or multiple-dose administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aafc2dd-744d-4726-828f-70355aee6f70 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:601a18ed-d66e-498f-a804-f1a3330827d4 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87b8cd3c-2849-4b50-b63e-9ea379165c07 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b735e92d-eb1a-6fc1-e053-2995a90afce2 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81cdae6f-99d7-468b-9ab8-fecb1d42298d (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:378461f2-7271-44a3-9da3-b39970b65d3a (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560df50c-e2c4-459f-9d89-bf7e6588949e (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45e07bdd-78f9-4055-9de3-646e67de7eaf (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0f73459-baeb-42a7-be48-2c3647d9b205 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99a490cc-e41d-436b-9cf3-8facb7ac714f (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum plasma concentrations of about 18 ng/mL of albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.
4.6 hours
- Numeric value
- 4.6
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ed73618-be3a-4331-9509-6401258f791f (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7043bc12-8a58-8ff8-e053-2a91aa0ab627 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6dc143e7-6bab-42c8-b3e9-9d604d202e73 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54d90668-5237-4330-e054-00144ff88e88 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:825975b1-a4a9-78ca-e053-2a91aa0a3948 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb8d669-b91c-46f1-8a86-19f504840eff (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4378c5b0-529f-44b4-bdf1-e9f2631df8cd (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b25d9d6b-eb4c-452e-89ef-10e611deebd6 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d92c5d6b-ff10-4087-36a2-1cfc464cb967 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd0389e0-3713-42e0-8ef2-3bb97676fded (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:767a1504-1e04-1e06-e053-2a91aa0aa4b6 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04c8a345-0a0d-5a01-e063-6294a90a40d2 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aff836e4-34f2-4ab9-bbf8-0c41ac848cb0 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa6d5c00-46a5-4f93-95e4-09319abfe71e (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77d34a3c-ccc6-420a-ad31-a1af55f7de76 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Apparent terminal plasma half-life of albuterol is approximately 4.6 hours.
5 to 6 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f261a9b-65d9-408a-8609-c1b3809b8b4b (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:230d66fc-f62c-42a6-adb3-0a0f879c8ad4 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum albuterol plasma levels are usually obtained between 2 and 3 hours after dosing, and the elimination half-life is 5 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3fa0068-fd12-45de-818e-e929fb45ba05 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum albuterol plasma levels are usually obtained between 2 and 3 hours after dosing, and the elimination half-life is 5 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdb4ac5a-bf0d-4896-89f7-1828c081b79e (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:895dff1c-d21c-4470-b021-a5b68364c1ec (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Maximum albuterol plasma levels are usually obtained between 2 and 3 hours after dosing, and the elimination half-life is 5 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3236f82c-14e9-dfd4-e063-6294a90ac43d (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecc00500-58b8-491f-80df-dc6c89a08cae (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.
Projected row 40
- Medicine slug
- albuterol
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 113
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9324e2eb-26fd-4f14-9f10-e5aa467306f4 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Published literature suggests that albuterol exhibits low in vitro plasma protein binding (10%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:667ce3ec-5217-4b10-b712-f3e54fbbf087 (opens source in a new tab)
Albuterol label
Version not recorded · Effective date not recorded
Published literature suggests that albuterol exhibits low in vitro plasma protein binding (10%).
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=30Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.